"For those using GLP-1s to manage diabetes, medical cost growth was six percentage points lower than non-users at 30 months and nine percentage points lower for those with at least 80 percent adherence.... [F]emale GLP-1 users experienced approximately a 50 percent lower incidence of ovarian cancer and about a 14 percent lower incidence of breast cancer compared to female non-users over the study period.... The reduction in [major adverse cardiovascular events] for female users reached 47 percent, compared to 26 percent for male users, highlighting an even stronger cardiovascular benefit for women."  MORE >>